{"id":19404,"date":"2025-07-18T16:55:09","date_gmt":"2025-07-18T16:55:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/19404\/"},"modified":"2025-07-18T16:55:09","modified_gmt":"2025-07-18T16:55:09","slug":"prostate-cancer-treatment-market-size-to-reach-usd-34-28-billion-by-2034","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/19404\/","title":{"rendered":"Prostate Cancer Treatment Market Size to Reach USD 34.28 Billion by 2034"},"content":{"rendered":"

<\/p>\n

The global prostate
\ncancer treatment market size<\/a> is expected to be worth around 34.28
\nbillion by 2034, increasing from USD 16.05 billion in 2025, representing a
\nhealthy CAGR of 8.8% from 2025 to 2034.<\/p>\n

\"Prostate<\/p>\n

The prostate cancer treatment market is
\nexpanding due to this treatment includes active surveillance, radiation
\ntherapy<\/a>, surgery<\/a>,
\nhormonal therapy, immunotherapy<\/a>,
\nand chemotherapy. Experts have advanced targeted therapies based on PSMA, the
\nsame protein that is used for imaging prostate cancer.<\/p>\n

The Complete Study is Now Available for
\nImmediate Access | Download the Sample Pages of this Report@ https:\/\/www.novaoneadvisor.com\/report\/sample\/6340<\/a>\n<\/p>\n

Prostate Cancer Treatment Market
\nHighlights:<\/p>\n

\u2022 North America dominated the prostate
\ncancer treatment market revenue shares in 2024.<\/p>\n

\u2022 Asia-Pacific is expected to grow at the
\nfastest CAGR in the market during the forecast period.<\/p>\n

\u2022 By drug class, the hormonal therapy
\nsegment dominated the market with a revenue share.<\/p>\n

\u2022 By drug class, the immunotherapy segment
\nis expected to grow at the fastest CAGR in the market during the studied years.<\/p>\n

\u2022 By distribution channel, the hospital
\npharmacies segment held the largest market share.<\/p>\n

\u2022 By distribution channel, the online
\npharmacies segment is expected to grow at the fastest CAGR in the market during
\nthe studied years.<\/p>\n

Market Overview and Industry Potential<\/p>\n

The prostate cancer treatment market is
\nexpanding due to the hormonal therapy and androgen deprivation are developing
\nas novel and improved options for managing hormone-sensitive and
\ncastration-resistant PC. Prostate
\ncancer<\/a> is cured, predominantly when detected early and confined to the
\nprostate gland. The possibility of a cure depends on factors such as the stage
\nof cancer at diagnosis and individual patient characteristics. Treatment for
\nprostate cancer is based on a person’s circumstances. <\/p>\n

\u2022 For Instance, In June 2025, Orion\u2019s
\ncollaboration partner Bayer announced that the U.S. Food and Drug
\nAdministration (FDA) had approved the oral androgen receptor inhibitor
\ndarolutamide in combination with androgen deprivation therapy (ADT) for use in
\npatients with metastatic castration-sensitive prostate cancer (mCSPC), which is
\nalso called metastatic hormone-sensitive prostate cancer (mHSPC).<\/p>\n

Recent Treatment Approved for Treatment
\nof Prostate Cancer in 2025<\/p>\n

Treatment<\/p>\n

Advantages<\/p>\n

OncoAssure Prostate Tests<\/p>\n

Improve risk assessment and help guide treatment decisions.<\/p>\n

\u00a0<\/p>\n

177Lu-PSMA-617 (Pluvicto\u00ae)<\/p>\n

It delivers radiation that damages DNA and destroys the
\n cancer cell.<\/p>\n

olaparib<\/p>\n

Improved progression-free survival, overall survival, and
\n patient-reported outcomes<\/p>\n

\u00a0<\/p>\n

ASCO 2025<\/p>\n

AI test determines the best prostate cancer treatment<\/p>\n

Prostate cancer is the second most common
\ncancer in men. While prostate cancer rates have declined in the U.S., advanced
\nprostate cancer cases have increased. The incidence and mortality of prostate
\ncancer globally are associated with growing age, with the average age at the
\ntime of diagnosis being 66 years. The choice of treatment strategy is dependent
\non many factors, such as patient preference and quality of life aspects.
\nClinicians treat and manage prostate cancer in various ways, depending on the
\ncancer stage and different factors.<\/p>\n

What are Latest Trends in Prostate
\nCancer Treatment Market?<\/p>\n

\u2022 In April 2025, Tata Memorial Centre
\nLaunches \u2018MenCan\u2019 Initiative to Address Rising Burden of Male Cancers in India.
\nIn a significant step towards advancing cancer care for men in India, the Tata
\nMemorial Centre (TMC) has officially launched MenCan, a dedicated initiative by
\nthe Urologic Oncology Disease Management Group (URO DMG). This nonprofit,
\nnon-commercial initiative is focused on addressing prostate, penile, and
\ntesticular cancers, three types of male cancers that are seeing a rising
\nincidence across the country.<\/p>\n

\u2022 In February 2025, ZERO Prostate Cancer
\n(ZERO), the nation’s leading advocacy and support foundation for prostate
\ncancer awareness, announced the launch of Blitz the Barriers during Cancer
\nPrevention Month. This bold initiative, with a target fund goal of $20 million,
\nmarks the most ambitious project in the history of U.S. prostate cancer patient
\nprograms. It aims to save lives by addressing critical disparities in prostate
\ncancer outcomes, especially among Black men, Veterans, and rural underserved
\ncommunities. <\/p>\n

\u2022 In January 2025, the American Urological
\nAssociation Education and Research, Inc. (AUAER) is proud to announce a
\ncollaboration with Pfizer Medical Grants & Partnerships (GMGP) to offer
\n$1.5 million in grant funding to urology and urologic oncology health
\ninstitutions and organizations. This joint Request for Proposals (RFP) is
\ndesigned to address critical gaps in patient care for individuals with advanced
\nprostate cancer (APC) and support novel, quality improvement, solution-based
\nprojects to address these challenges.<\/p>\n

\u2022 In July 2025, RedHill Biopharma Ltd., a
\nspecialty biopharmaceutical company, announced the initiation of patient
\nrecruitment into the Phase 2 study evaluating the efficacy of opaganib3 in
\ncombination with darolutamide4 in men with metastatic castrate-resistant
\nprostate cancer (mCRPC), sponsored by the Australian and New Zealand Urogenital
\nand Prostate Cancer Trials Group Ltd. in Australia, and supported by Bayer and
\nRamsay Hospital Research Foundation.<\/p>\n

Recent Advancement in ProstaScint
\nTechnology: Market\u2019s Largest Potential<\/p>\n

Current developments in image overlay, with
\ngrowing experience in interpreting the scan, created a transformed interest in
\nintegrating Prosta Scint into the medical treatment of prostate cancer.
\nProstaScint imaging enhances the prediction of lymph node contribution in
\npatients with more challenges for extra-prostatic disease. Its potential to
\nidentify metastatic foci has led to optimism related to improved staging of
\npatients with novel diagnosed and recurrent disease. Prostascint is that it
\nenables to survey of the whole body, thus allowing the detection of occult
\nmetastasis, which has a major impact on prostate cancer staging.<\/p>\n

\u2022 For Instance, In May 2025, Astellas
\nPharma Inc. and Pfizer Inc. announced longer-term follow-up results from an
\nopen-label extension of the Phase 3 ARCHES study, reporting a five-year follow
\nup of overall survival (OS) benefits and a 30% reduction in the risk of death
\nin men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with
\nXTANDI, an androgen receptor pathway inhibitor, plus androgen deprivation
\ntherapy (ADT) compared to placebo plus ADT.<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/6340<\/a>\n<\/p>\n

Report Scope of Prostate Cancer
\nTreatment Market<\/p>\n

Report Coverage<\/p>\n

Details<\/p>\n

Market Size in 2025<\/p>\n

USD 16.05 Billion<\/p>\n

Market Size by 2034<\/p>\n

USD 34.28 Billion<\/p>\n

Growth Rate From 2025
\n to 2034<\/p>\n

CAGR of 8.8%<\/p>\n

Base Year<\/p>\n

2024<\/p>\n

Forecast Period<\/p>\n

2025-2034<\/p>\n

Segments Covered<\/p>\n

Type, Sales Channel,
\n Region<\/p>\n

Market Analysis
\n (Terms Used)<\/p>\n

Value (US$ Million\/Billion)
\n or (Volume\/Units)<\/p>\n

Regional scope<\/p>\n

North America;
\n Europe; Asia Pacific; Latin America; MEA<\/p>\n

Key Companies
\n Profiled<\/p>\n

Johnson & Johnson
\n Services, Inc., Astellas Pharma Inc., Eli Lilly and Company, Sanofi, Ipsen
\n Pharma, Bayer AG, AstraZeneca, Bausch Health Companies Inc., Merck & Co.,
\n Inc., Pfizer Inc.<\/p>\n

Prostate Cancer Treatment Market
\nSegmentation Analysis:<\/p>\n

By Drug Class Analysis:<\/p>\n

The hormonal therapy segment dominated in
\nthe prostate cancer treatment market, as this therapy blocks or lowers the
\nnumber of hormones in the body to stop or slow down the development of cancer.
\nIt stops the hormones from being made or stops them from making cancer cells
\ngrow and divide. Hormone
\ntherapy<\/a> is generally the primary treatment choice for advanced prostate
\ncancer. It is generally not used by itself to manage early-stage prostate
\ncancer. Hormone therapy is used in combination with other treatments.<\/p>\n

On the other hand, the immunotherapy
\nsegment is expected to grow significantly during the forecast period, as
\nimmunotherapy modulates and strengthens immune responses against prostate
\ncancer. Neoplastic cells naturally escape from the control of the immune
\nsystem, and the vital aim of immune therapy is to bring the control back. <\/p>\n

Immunotherapy remains an appealing
\ntreatment option for prostate cancer with promise. Immunotherapy is the use of
\ndrugs to stimulate a person’s immune system to recognize and destroy cancer
\ncells more effectively.<\/p>\n

By Distribution Channel Analysis:<\/p>\n

The hospital pharmacies segment dominated
\nthe market in 2024, as hospital pharmacy is a great source of advice for
\npatients. They are called upon to recommend safe combinations of medications or
\nsolutions to address patient difficulties. Hospital pharmacy provides data on
\npotential adverse effects and identifies that medicines are well-matched with
\nexisting medications. They often monitor the effects of treatments to confirm
\nthat they are offering appropriate, safe, and effective treatments to the end
\nuser.<\/p>\n

\"A<\/p>\n

On the other hand, the online pharmacies
\nsegment is expected to grow at the fastest CAGR in the market during the
\nforecast period, as it offers unparalleled convenience to customers. Online
\npharmacies enhance the consumer healthcare experience by affording medicine
\nefficiency, greater privacy, and enhanced access to medicines. Online
\npharmacies are a link between patients and crucial medications, especially for
\nthose living in remote or underserved areas.<\/p>\n

By Regional Insights<\/p>\n

North America dominated the clinical cancer
\nnext-generation sequencing market in 2024, due to the increasing prostate
\ncancer incidence and mortality rates are strongly related to age, with the
\nhighest incidence being seen in older men in the North America region.\u00a0 Around
\n1 in 8 men are diagnosed with this cancer in their lifetime.<\/p>\n

\u2022 For Instance, In March 2025, Novartis
\nannounced that the US Food and Drug Administration (FDA) approved Pluvicto for
\npatients with prostate-specific membrane antigen (PSMA)-positive metastatic
\ncastration-resistant prostate cancer (mCRPC) who have been treated with an
\nandrogen receptor pathway inhibitor therapy and are considered appropriate to
\ndelay chemotherapy.<\/p>\n

U.S. Prostate Cancer Treatment Market
\nTrends:<\/p>\n

In 2024, almost 300,000 men in the United
\nStates were diagnosed with prostate cancer, and slightly more than 35,000 died
\nfrom it. The U.S. adopts progressive diagnostic tools for prostate cancer
\ntreatment, as advanced diagnostics also bring health system efficacies through
\nreducing the use of treatments that would be unsuccessful for an individual and
\nproviding greater automation of diagnostic devices and clinical workflows. <\/p>\n

Why Asia Pacific is the Fastest Growing
\nin the Prostate Cancer Treatment Market?<\/p>\n

The incidence rates of prostate cancer
\nincreased in the Asia Pacific is due to various factors, including genetics,
\nnutritional status, lifestyle, environmental factors, physical activity, race,
\nsmoking, and other characteristics. The usage of next-generation imaging, novel
\ntreatment combinations, and genetic testing is increasing the complexity and
\nduration of prostate cancer management. Increasing adoption of robot-driven
\nsurgeries and minimally invasive processes.<\/p>\n

Top Companies in the Prostate Cancer
\nTreatment Market<\/p>\n

\u2022 Johnson
\n& Johnson Services, Inc.<\/a><\/p>\n

\u2022 Astellas
\nPharma Inc<\/a>.<\/p>\n

\u2022 Eli Lilly and Company<\/p>\n

\u2022 Sanofi<\/a><\/p>\n

\u2022 Ipsen Pharma<\/p>\n

\u2022 Bayer
\nAG<\/a><\/p>\n

\u2022 AstraZeneca<\/a><\/p>\n

\u2022 Bausch Health Companies Inc.<\/p>\n

\u2022 Merck & Co., Inc.<\/p>\n

\u2022 Pfizer
\nInc.<\/a><\/p>\n

What is Going Around the Globe?<\/p>\n

\u2022 In July 2025, Pfizer Inc<\/a>. and Astellas Pharma U.S.
\nInc. announced positive topline results from the overall survival analysis from
\nthe Phase 3 EMBARK study evaluating XTANDI, in combination with leuprolide and
\nas a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer
\nwith biochemical recurrence (BCR) at high risk for metastasis. <\/p>\n

\u2022 In June 2024, Lantheus Holdings, Inc<\/a>. announced
\nits acquisition of the global rights of Life Molecular Imaging\u2019s RM2, targeting
\nthe gastrin-releasing peptide receptor (GRPR), including the associated
\nadvanced, clinical-stage radiotherapeutic and radio diagnostic pair, referred
\nto as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2. This acquisition strengthens Lantheus\u2019
\npresence in prostate cancer and expands its pipeline to include breast and
\nother cancers. The agreement includes global rights1 to this radiotheranostic
\npair for an upfront payment of $35 million and potential regulatory milestone
\npayments plus royalties.<\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact at\u00a0sales@novaoneadvisor.com<\/a> \u00a0|
\n+1 804 441 9344<\/p>\n

Related Report \u2013 <\/p>\n

\u2022 Tendonitis Treatment Market- https:\/\/www.novaoneadvisor.com\/report\/tendonitis-treatment-market<\/a>\n<\/p>\n

\u2022 U.S. Clinical Trials Market – https:\/\/www.novaoneadvisor.com\/report\/us-clinical-trials-market<\/a>\n<\/p>\n

\u2022 Alzheimer\u2019s Disease Diagnostics Market
\n– https:\/\/www.novaoneadvisor.com\/report\/alzheimers-disease-diagnostics-market<\/a>\n<\/p>\n

\u2022 U.S. DNA Manufacturing Market – https:\/\/www.novaoneadvisor.com\/report\/us-dna-manufacturing-market<\/a>\n<\/p>\n

\u2022 U.S. Medical Device Contract
\nManufacturing Market – https:\/\/www.novaoneadvisor.com\/report\/us-medical-device-contract-manufacturing-market<\/a>\n<\/p>\n

\u2022 Human DNA Vaccines Market – https:\/\/www.novaoneadvisor.com\/report\/human-dna-vaccines-market<\/a>\n<\/p>\n

\u2022 U.S. Gastric Cancer Diagnostics Market
\n– https:\/\/www.novaoneadvisor.com\/report\/us-gastric-cancer-diagnostics-market<\/a>\n<\/p>\n

\u2022 U.S. Pharmaceutical CDMO Market – https:\/\/www.novaoneadvisor.com\/report\/us-pharmaceutical-cdmo-market<\/a>\n<\/p>\n

Segments Covered in the Report<\/p>\n

This report forecasts revenue growth at
\ncountry levels and provides an analysis of the latest industry trends in each
\nof the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
\nhas segmented the Prostate Cancer Treatment Market.<\/p>\n

By Drug Class <\/p>\n

\u2022 Hormonal Therapy<\/p>\n

\u2022 Chemotherapy<\/p>\n

\u2022 Immunotherapy<\/p>\n

\u2022 Targeted Therapy<\/p>\n

\u2022 Others<\/p>\n

By Distribution Channel <\/p>\n

\u2022 Hospital Pharmacies<\/p>\n

\u2022 Drug Stores & Retail Pharmacies<\/p>\n

\u2022 Online Pharmacies<\/p>\n

By Regional<\/p>\n

\u2022 North America<\/p>\n

\u2022 Europe<\/p>\n

\u2022 Asia Pacific<\/p>\n

\u2022 Latin America<\/p>\n

\u2022 Middle East and Africa (MEA)<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/6340<\/a>\n<\/p>\n

About-Us<\/p>\n

Nova One Advisor is a global leader
\nin market intelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire
\nbiotech and pharmaceutical value chain, empowering startups, global
\nenterprises, investors, and research institutions that are pioneering the next
\ngeneration of therapies in regenerative medicine, oncology, and precision
\nmedicine. <\/p>\n

Web: https:\/\/www.novaoneadvisor.com\/<\/a><\/p>\n

Contact Us<\/p>\n

USA:\u00a0+1 804 420 9370<\/p>\n

Email: sales@novaoneadvisor.com<\/a><\/p>\n

For Latest Update
\nFollow Us: LinkedIn<\/a><\/p><\/p>\n","protected":false},"excerpt":{"rendered":"The global prostate cancer treatment market size is expected to be worth around 34.28 billion by 2034, increasing…\n","protected":false},"author":2,"featured_media":19405,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[28,112],"class_list":{"0":"post-19404","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/19404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=19404"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/19404\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/19405"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=19404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=19404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=19404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}